JP2019533652A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533652A5
JP2019533652A5 JP2019517257A JP2019517257A JP2019533652A5 JP 2019533652 A5 JP2019533652 A5 JP 2019533652A5 JP 2019517257 A JP2019517257 A JP 2019517257A JP 2019517257 A JP2019517257 A JP 2019517257A JP 2019533652 A5 JP2019533652 A5 JP 2019533652A5
Authority
JP
Japan
Prior art keywords
subject
cdk1
clk2
cell
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019517257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533652A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/054442 external-priority patent/WO2018064545A1/en
Publication of JP2019533652A publication Critical patent/JP2019533652A/ja
Publication of JP2019533652A5 publication Critical patent/JP2019533652A5/ja
Pending legal-status Critical Current

Links

JP2019517257A 2016-09-30 2017-09-29 がんを処置するための二重clk/cdk1阻害剤 Pending JP2019533652A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402876P 2016-09-30 2016-09-30
US62/402,876 2016-09-30
PCT/US2017/054442 WO2018064545A1 (en) 2016-09-30 2017-09-29 Dual clk/cdk1 inhibitors for cancer treatment

Publications (2)

Publication Number Publication Date
JP2019533652A JP2019533652A (ja) 2019-11-21
JP2019533652A5 true JP2019533652A5 (enExample) 2020-11-12

Family

ID=61760971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517257A Pending JP2019533652A (ja) 2016-09-30 2017-09-29 がんを処置するための二重clk/cdk1阻害剤

Country Status (5)

Country Link
US (2) US10722515B2 (enExample)
EP (2) EP4086257A1 (enExample)
JP (1) JP2019533652A (enExample)
CN (2) CN109937039A (enExample)
WO (1) WO2018064545A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
US10722515B2 (en) 2016-09-30 2020-07-28 Sri International Dual CLK/CDK1 inhibitors for cancer treatment
US20220062240A1 (en) * 2018-06-26 2022-03-03 Biosplice Therapeutics, Inc. Methods of treating cancer using a clk inhibitor
WO2022002118A1 (zh) * 2020-07-01 2022-01-06 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
CN113384703B (zh) * 2021-06-21 2023-03-10 深圳市第二人民医院(深圳市转化医学研究院) Dhx34基因的表达抑制剂在制备抑制肝癌细胞转移和侵袭的药物中的应用
CN120289460A (zh) * 2024-01-09 2025-07-11 中国科学院合肥物质科学研究院 含有嘌呤环的化合物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
AU7296896A (en) * 1995-11-01 1997-05-22 Novartis Ag Purine derivatives and processes for their preparation
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
WO2001044257A1 (en) * 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
JP2003531111A (ja) * 1999-12-17 2003-10-21 アライアッド・ファーマシューティカルズ・インコーポレーテッド プロトンポンプインヒビター
IL150061A0 (en) * 1999-12-17 2002-12-01 Ariad Pharma Inc Purine derivatives
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2009085226A2 (en) * 2007-12-21 2009-07-09 Sirtris Pharmaceuticals, Inc. Inhibitors of cdc2-like kinases (clks) and methods of use thereof
JP5918693B2 (ja) * 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Egfr阻害剤及び疾患の治療方法
WO2013144532A1 (en) * 2012-03-30 2013-10-03 Astrazeneca Ab 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
EP2874631A1 (en) * 2012-05-15 2015-05-27 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
EP2968536B1 (en) * 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
UA115388C2 (uk) * 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
JP2019517257A (ja) 2016-05-31 2019-06-24 ザ ジェイ. デヴィッド グラッドストーン インスティテューツ 幹細胞をニューロンに分化するインビトロ法、及びこの方法を用いて生成されたニューロン
US10722515B2 (en) * 2016-09-30 2020-07-28 Sri International Dual CLK/CDK1 inhibitors for cancer treatment

Similar Documents

Publication Publication Date Title
JP2019533652A5 (enExample)
JP2017008088A5 (enExample)
JP2018517686A5 (enExample)
CN113767106A (zh) 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途
JP2018536636A5 (enExample)
RU2017143776A (ru) Пролекарства альвоцидиба, имеющие повышенную биодоступность
JP2019510746A5 (enExample)
JP2019506392A5 (enExample)
JP2016515561A5 (enExample)
CN111065639A (zh) 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
JP2020514356A5 (enExample)
JP2018535951A5 (enExample)
JP2019501204A5 (enExample)
RU2015118135A (ru) Содержащие заместители бензольные соединения
KR20180043356A (ko) 담관암의 치료법
JP2013527249A5 (enExample)
JP2012502954A5 (enExample)
JP2018522045A5 (enExample)
JP2016539134A5 (enExample)
JP2014510729A5 (enExample)
JP2016531885A5 (enExample)
JP2018534288A5 (enExample)
JP2016529285A5 (enExample)
JP2021080296A5 (enExample)
JP2017513908A5 (enExample)